Dimebon drug trial fails to meet primary endpoint: Medivation, Pfizer report
The data demonstrated that Dimebon did not achieve statistically significant results for either of the two co-primary endpoints including the Alzheimer’s Disease Assessment Scale and the Alzheimer’s Disease
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.